Abstract
Lenvatinib (Lenvima™) is a multitargeted receptor kinase inhibitor that inhibits the kinase activities of vascular endothelial-derived growth factor receptors 1, 2 and 3, fibroblast growth factor receptors 1, 2, 3 and 4, platelet-derived growth factor receptor α, RET and KIT. In addition to their role in normal cellular function, these kinases have been implicated in pathogenic angiogenesis, tumour growth and cancer progression. Lenvatinib is being developed by Eisai Co. Ltd for the treatment of solid tumours, primarily for differentiated thyroid cancer, and other malignancies. A capsule formulation of the drug has received approval in the USA for use in locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer. Lenvatinib is in pre-registration for this indication in the EU, Australia, Brazil, Canada, Japan, South Korea, Russia, Singapore and Switzerland, and is in phase 3 development in Argentina, Chile and Thailand. Lenvatinib has orphan designation in the EU and Japan for use in differentiated thyroid cancer. In addition, an ongoing global, phase 3 trial is evaluating the use of lenvatinib as first-line treatment in unresectable hepatocellular carcinoma. This article summarize...Continue Reading
References
Jul 22, 2005·Melanoma Research·Meri-Sisko VuoristoPirkko Kellokumpu-Lehtinen
Oct 19, 2007·International Journal of Cancer. Journal International Du Cancer·Junji MatsuiMakoto Asada
Sep 4, 2008·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Junji MatsuiMakoto Asada
Feb 23, 2010·Gynecologic Oncology·Alessandro D Santin
Jan 13, 2011·International Journal of Cancer. Journal International Du Cancer·Skjalg BruheimØystein Fodstad
Mar 5, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Kazuhiko YamadaTomohide Tamura
Jul 26, 2011·BMC Cancer·Hilary GlenValerie G Brunton
Apr 21, 2012·British Journal of Cancer·D S BossT R J Evans
Jul 17, 2013·Cancer Letters·Kiyoshi OkamotoAkihiko Tsuruoka
Jul 19, 2013·British Journal of Cancer·M NishioT Tamura
Nov 6, 2013·Cancer Chemotherapy and Pharmacology·Ana M MolinaM Dror Michaelson
Feb 20, 2014·International Journal of Clinical Pharmacology and Therapeutics·Robert ShumakerKun Chen
Mar 25, 2014·Cancer Chemotherapy and Pharmacology·Robert C ShumakerBorje Darpo
Jun 27, 2014·European Journal of Dentistry·Francesca Maria Giovanna PiliValentino Garau
Jul 16, 2014·Clinical Drug Investigation·Robert C ShumakerMin Ren
Jul 23, 2014·BMC Cancer·Noriyuki KoyamaTomohide Tamura
Sep 10, 2014·Vascular Cell·Yuji YamamotoAkihiko Tsuruoka
Sep 11, 2014·Journal of Clinical Pharmacology·Robert ShumakerMin Ren
Oct 9, 2014·Journal of Thyroid Research·Osamu TohyamaYasuhiro Funahashi
Nov 5, 2014·Therapeutic Advances in Medical Oncology·Francis Worden
Nov 8, 2014·Investigational New Drugs·Anne-Charlotte DubbelmanJos H Beijnen
Jan 2, 2015·Therapeutic Advances in Medical Oncology·T Alonso-GordoaEnrique Grande
Jan 16, 2015·ACS Medicinal Chemistry Letters·Kiyoshi OkamotoJunji Matsui
Feb 12, 2015·The New England Journal of Medicine·Martin SchlumbergerSteven I Sherman
Nov 13, 2015·Nihon yakurigaku zasshi. Folia pharmacologica Japonica·Akihiko TsuruokaYasuhiro Funahashi
Citations
Feb 13, 2016·Targeted Oncology·James E Frampton
Sep 19, 2017·Expert Opinion on Drug Safety·E GrandeJ Larkin
Oct 31, 2017·Current Oncology Reports·Paola JimenezCamilo Jimenez
May 14, 2019·Archiv der Pharmazie·Eman E NasrMohammed A M Massoud
Sep 29, 2019·Expert Opinion on Investigational Drugs·Dan WangYi Zhang
Mar 31, 2016·Oncotarget·Chun-Han ChenYun Yen
Apr 1, 2017·Drugs·Roy LirovMark S Cohen
Apr 18, 2019·Drugs·Zaina T Al-SalamaLesley J Scott
Nov 14, 2018·Current Oncology Reports·Ying L Liu, Dmitriy Zamarin
Mar 15, 2019·Journal of Hematology & Oncology·Shuang QinKongming Wu
Nov 7, 2019·Biomolecules·Javad Sharifi-RadWilliam C Cho
May 10, 2020·European Journal of Clinical Pharmacology·Jiaming LiDi Zhao
Oct 24, 2017·The Kurume Medical Journal·Jun-Ichi OhkuboHideaki Suzuki
Feb 2, 2019·Current Vascular Pharmacology·Cecilie BudolfsenNils Erik Magnusson
Nov 18, 2019·Advanced Drug Delivery Reviews·Xiaozhong HuangHanry Yu
Nov 3, 2020·Expert Review of Gastroenterology & Hepatology·Hui Li
Apr 9, 2021·Bioorganic Chemistry·Sarinya PalakhachanePanupun Limpachayaporn
Apr 27, 2021·Frontiers in Oncology·Kamila KitowskaRafal Sadej
May 5, 2021·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jaume CapdevilaToni Ibrahim
May 24, 2021·Bioorganic Chemistry·Mohammed M AlanaziIbrahim H Eissa
May 22, 2021·Toxicology and Applied Pharmacology·Aysenur Gunaydin AkyildizBuket Alpertunga
Aug 4, 2021·Journal of Enzyme Inhibition and Medicinal Chemistry·Mohammed M AlanaziAlaa Elwan